Santen Pharmaceutical Co., Ltd.
4536.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | ¥8,062,000 | ¥5,878,000 | ¥8,782,000 | ¥8,693,000 |
| Dep. & Amort. | ¥4,691,000 | ¥4,497,000 | ¥4,399,000 | ¥4,507,000 |
| Deferred Tax | ¥0 | ¥0 | ¥0 | ¥0 |
| Stock-Based Comp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Change in WC | -¥8,280,000 | -¥1,910,000 | ¥2,037,000 | ¥2,098,000 |
| Other Non-Cash | ¥1,380,000 | -¥745,000 | ¥3,672,000 | -¥1,568,000 |
| Operating Cash Flow | ¥5,853,000 | ¥7,720,000 | ¥18,890,000 | ¥13,730,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -¥7,290,000 | -¥1,856,000 | -¥2,764,000 | -¥3,815,000 |
| Net Acquisitions | ¥0 | ¥0 | ¥0 | ¥0 |
| Inv. Purchases | -¥103,000 | ¥0 | -¥1,573,000 | ¥0 |
| Inv. Sales/Matur. | ¥0 | ¥0 | ¥3,433,000 | ¥1,294,000 |
| Other Inv. Act. | ¥13,000 | -¥336,000 | -¥72,000 | -¥248,000 |
| Investing Cash Flow | -¥7,380,000 | -¥2,192,000 | -¥976,000 | -¥2,769,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | ¥0 | -¥881,000 | ¥1,000 | ¥0 |
| Stock Issued | ¥0 | ¥0 | ¥0 | ¥0 |
| Stock Repurch. | -¥19,743,000 | -¥8,050,000 | ¥0 | -¥13,513,000 |
| Dividends Paid | -¥71,000 | -¥6,408,000 | -¥67,000 | -¥5,876,000 |
| Other Fin. Act. | -¥808,000 | -¥3,000 | -¥795,000 | -¥828,000 |
| Financing Cash Flow | -¥20,622,000 | -¥15,342,000 | -¥861,000 | -¥20,217,000 |
| Forex Effect | ¥1,131,000 | ¥1,394,000 | -¥1,907,000 | ¥2,665,000 |
| Net Chg. in Cash | -¥21,018,000 | -¥8,419,000 | ¥15,146,000 | -¥6,590,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | ¥84,578,000 | ¥92,997,000 | ¥77,851,000 | ¥84,441,000 |
| End Cash | ¥63,560,000 | ¥84,578,000 | ¥92,997,000 | ¥77,851,000 |
| Free Cash Flow | ¥4,321,000 | ¥5,864,000 | ¥17,963,000 | ¥10,674,000 |